Developments in Biological Standardization, volume 73. Pertussis: Evaluation and Research on Acellular Pertussis Vaccines
Corbel, M. J.
Journal of Medical Microbiology 38(2): 155-156
1993
ISSN/ISBN: 0022-2615 DOI: 10.1099/00222615-38-2-155aDocument Number: 424840
Document emailed within 0-6 h
Related Documents
Blumberg, D.A.; Pineda, E.; Cherry, J.D.; Caruso, A.; Scott, J.V. 1992: The agglutinin response to whole-cell and acellular pertussis vaccines is Bordetella pertussis--strain dependent American Journal of Diseases of Children 146(10): 1148-1150Rennels, M.B.; Reed, G.F.; Decker, M.D.; Edwards, K.M.; Pichichero, M.E.; Deloria, M.A.; Englund, J.A.; Anderson, E.L.; Steinhoff, M.C.; Deforest, A. 1995: Simultaneous administration of Haemophilus influenzae type b vaccine with acellular or whole-cell pertussis vaccine: effects on reactogenicity and immune responses to pertussis vaccines Pediatrics 96(3 Pt 2): 576-579
Heijbel, H.; Rasmussen, F.; Olin, P. 1997: Safety evaluation of one whole-cell and three acellular pertussis vaccines in Stockholm trial II Developments in Biological Standardization 89: 99-100
Isomura, S.; Suzuki, S.; Sato, Y. 1985: Clinical efficacy of the Japanese acellular pertussis vaccine after intrafamiliar exposure to pertussis patients Developments in Biological Standardization 61: 531-537
Edwards, K.M.; Lawrence, E.; Wright, P.F. 1986: Diphtheria, tetanus, and pertussis vaccine. A comparison of the immune response and adverse reactions to conventional and acellular pertussis components American Journal of Diseases of Children 140(9): 867-871
Chuprinina, R.P.; Alekseeva, I.A.; Ozeretskovskiĭ, N.A. 2006: Prophylaxis of pertussis: development and use of acellular pertussis vaccine Zhurnal Mikrobiologii Epidemiologii i Immunobiologii 2006(1): 99-105
Corbel, M.J.; Xing, D.K. 1997: A consideration of control requirements for acellular pertussis vaccines Developments in Biological Standardization 89: 343-347
Trollfors, B. 1997: Factors influencing antibody responses to acellular pertussis vaccines Developments in Biological Standardization 89: 279-282
Storsaeter, J.; Gustafsson, L. 1997: Absolute efficacy of acellular pertussis vaccines in household settings Developments in Biological Standardization 89: 153-159
Rappuoli, R. 1996: Acellular pertussis vaccines: a turning point in infant and adolescent vaccination Infectious Agents and Disease 5(1): 21-28
Noble, G.R.; Bernier, R.H.; Esber, E.C.; Hardegree, M.C.; Hinman, A.R.; Klein, D.; Saah, A.J. 1987: Acellular and whole-cell pertussis vaccines in Japan. Report of a visit by US scientists JAMA 257(10): 1351-1356
Shek, L.Pei.Chi.; Khor, E.Sek.Hoon.; Tan, G.Huat.; Low, K.Tzay.; Ong, D.; Roy, J.; Han, H.Htay.; Bock, H.Ludwig.; Lee, B.Wah. 2003: Comparative study of the reactogenicity of a three-component acellular pertussis vaccine and whole-cell pertussis vaccine administered to healthy Singaporean infants Southeast Asian Journal of Tropical Medicine and Public Health 34(4): 863-868
Kallings, L.O.; Olin, P.; Storsaeter, J. 1988: Protective effect of 2 acellular pertussis vaccines in a double-blind placebo controlled clinical trial Lakartidningen 85(22): 1994-1996
Giuliano, M.; Mastrantonio, P.; Giammanco, A.; Bottone, M.; Piscitelli, A.; Di Tommaso, S.; Robino, L.; Basso, F.; D'Orazio, P. 1997: Antibody kinetics and long-term sero-prevalence in the Italian clinical trial of acellular pertussis vaccines Developments in Biological Standardization 89: 275-278
Christy, C.; Pichichero, M.E.; Reed, G.F.; Decker, M.D.; Anderson, E.L.; Rennels, M.B.; Englund, J.A.; Edwards, K.M.; Steinhoff, M.C. 1995: Effect of gender, race, and parental education on immunogenicity and reported reactogenicity of acellular and whole-cell pertussis vaccines Pediatrics 96(3 Pt 2): 584-587
Granoff, D.M.; Rappuoli, R. 1997: Are serological responses to acellular pertussis antigens sufficient criteria to ensure that new combination vaccines are effective for prevention of disease? Developments in Biological Standardization 89: 379-389
Redhead, K. 1996: Developments in pertussis vaccines leading to reduction and replacement of in vivo testing Developments in Biological Standardization 86: 263-270
Xing, D.; Canthaboo, C.; Douglas-Bardsley, A.; Yuen, C.T.; Prior, S.; Liu, Y.; Corbel, M. 2002: Developments in reduction and replacement of in vivo toxicity and potency tests for pertussis vaccines Developments in Biologicals 111: 57-68
Frühwirth, M.; Wolf, H.; Heininger, H.; Guggenbichler, J.P.; Stehr, E. 1995: Secretory IgA against pertussis toxin and surface structures of Bordetella pertussis in saliva of children with culture proven pertussis Advances in Experimental Medicine and Biology 371b: 777-783
Schmitt-Grohé, S.; Stehr, K.; Cherry, J.D.; Heininger, U.; Uberall, M.A.; Laussucq, S.; Eckhardt, T. 1997: Minor adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group Developments in Biological Standardization 89: 113-118